Viking Therapeutics, Inc.

Investor outlook for Pfizer’s oral GLP-1 agonist danuglipron was already dampened, but now the obesity drug has officially been discontinued, leaving the big pharma on the sidelines of the obesity dru

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of natio

New data from Novo Nordisk’s Phase III ESSENCE study of semaglutide in non-alcoholic steatohepatitis (NASH) unveiled at the American Association for the Study of Liver Disease conference on 19 Novembe